Medline Shares Slip as Legal and Regulatory Pressure Mount
Medline stock fell 2.0% in pre-market trading to $36.40 amid newly announced securities fraud investigations and renewed regulatory scrutiny after an FDA warning letter. The company has been coping with a post-earnings pullback driven by weaker profitability, tariff-related import costs and margin pressure, while a large late-May secondary share sa…